161 related articles for article (PubMed ID: 36245371)
21.
Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
[TBL] [Abstract][Full Text] [Related]
22. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis.
Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X
Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201
[TBL] [Abstract][Full Text] [Related]
23. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
24. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
25. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
26. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
Lu H; Wu J; Liang L; Wang X; Cai H
Front Immunol; 2022; 13():803355. PubMed ID: 35154117
[TBL] [Abstract][Full Text] [Related]
27. A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA.
Li H; Chen S; Mi H
Biomed Res Int; 2022; 2022():2449449. PubMed ID: 35669725
[TBL] [Abstract][Full Text] [Related]
28. LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
Du Y; Liu Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
Front Immunol; 2023; 14():1113756. PubMed ID: 37153545
[TBL] [Abstract][Full Text] [Related]
29. A prognostic model for bladder cancer based on cytoskeleton-related genes.
Peng C; Guo S; Yang Z; Li X; Su Q; Mo W
Medicine (Baltimore); 2023 Apr; 102(17):e33538. PubMed ID: 37115085
[TBL] [Abstract][Full Text] [Related]
30. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
Lin Y; Li T; Li Z; Shen C; Wu Z; Zhang Z; Li Z; Yang S; Wang Z; Li P; Fu C; Guo J; Hu H
Front Genet; 2023; 14():1097179. PubMed ID: 37091788
[No Abstract] [Full Text] [Related]
32. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
Gao X; Cai J
Front Genet; 2022; 13():865204. PubMed ID: 35571063
[No Abstract] [Full Text] [Related]
33. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
34. Identification of
Zhou R; Peng N; Li W
Front Immunol; 2022; 13():975503. PubMed ID: 36072584
[TBL] [Abstract][Full Text] [Related]
35. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
[TBL] [Abstract][Full Text] [Related]
36. Identification of immune-related and autophagy-related genes for the prediction of survival in bladder cancer.
Zhu Q; Zhang L; Deng Y; Tang L
BMC Genom Data; 2022 Aug; 23(1):60. PubMed ID: 35909123
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
Qiu Y; Ye W; Wang C; Zang J
Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
[TBL] [Abstract][Full Text] [Related]
38. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
39. Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
Zhang LH; Li LQ; Zhan YH; Zhu ZW; Zhang XP
Front Mol Biosci; 2021; 8():607090. PubMed ID: 33937319
[TBL] [Abstract][Full Text] [Related]
40. Identification of immune-related genes that predict prognosis and risk of bladder cancer: bioinformatics analysis of TCGA database.
Guo L; Wu Q; Ma Z; Yuan M; Zhao S
Aging (Albany NY); 2021 Jul; 13(15):19352-19374. PubMed ID: 34329197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
